Literature DB >> 15955677

Problematic drug use and drug use disorders in EU countries and Norway: an overview of the epidemiology.

Jürgen Rehm1, Robin Room, Wim van den Brink, Ludwig Kraus.   

Abstract

OBJECTIVE: To estimate the prevalence of drug use disorders in the European Union and Norway.
METHOD: Based on a systematic literature search and an expert survey, publications after 1990 on prevalence of drug use disorders (DUD, defined as drug dependence and drug abuse or harmful use) in EU countries and Norway were reviewed. The search included both direct estimations based on general population surveys using the DSM-IIIR, DSM-IV, or ICD-10 definitions of DUD; and indirect estimates based on other epidemiological methods, such as multiplier procedures based on treatment or legal data and capture-recapture techniques. The indirect methods did not use diagnostic criteria, but criteria based on duration and pattern of use, labelled as problematic drug use as a meaningful approximation.
RESULTS: The majority of DUD as estimated from direct methods using general population surveys were cannabis use disorders, usually not included in indirect estimates. The prevalence of thus defined disorders can be as high as 3%. For disorders other than cannabis use disorders (i.e. opioid, cocaine and amphetamine use disorders), indirect estimates of prevalence were consistently higher than those based on direct estimates, and ranged between 0.3% and 0.9% in European Union countries and Norway. Men have higher prevalence rates of DUD than women, but the difference was much less pronounced in general population surveys. Younger age (18-25 years) is the age group with the highest estimates.
CONCLUSION: General population surveys typically result in a serious underestimation of the prevalence of DUD other than cannabis use disorders, because many people with DUD are not reached by these surveys (hidden populations). Based on the more valid indirect estimates, it is concluded that problem drug use constitutes a relatively high burden of disease and social problems in Europe.

Entities:  

Mesh:

Year:  2005        PMID: 15955677     DOI: 10.1016/j.euroneuro.2005.04.004

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  12 in total

1.  Psychiatric disorders and the ICU: gaps and opportunities.

Authors:  Christoph Pechlaner; Bruno Mégarbane; W Wolfgang Fleischhacker
Journal:  Intensive Care Med       Date:  2008-09-18       Impact factor: 17.440

2.  The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: findings from the European Schizophrenia Cohort (EuroSC).

Authors:  Giuseppe Carrà; Sonia Johnson; Paul Bebbington; Matthias C Angermeyer; Dirk Heider; Traolach Brugha; Jean-Michel Azorin; Mondher Toumi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-17       Impact factor: 5.270

3.  Extra-medical stimulant dependence among recent initiates.

Authors:  Megan S O'Brien; James C Anthony
Journal:  Drug Alcohol Depend       Date:  2009-06-09       Impact factor: 4.492

4.  [Use of an outpatient treatment center for cannabis abuse].

Authors:  F Hölscher; U Bonnet; N Scherbaum
Journal:  Nervenarzt       Date:  2008-05       Impact factor: 1.214

5.  Cost of disorders of the brain in Italy.

Authors:  Maura Pugliatti; Patrik Sobocki; Ettore Beghi; Stefano Pini; Giovanni B Cassano; A Carlo Altamura; Sara Pozzoli; Giulio Rosati
Journal:  Neurol Sci       Date:  2008-05-16       Impact factor: 3.307

6.  Key future research questions on mediators and moderators of behaviour change processes for substance abuse.

Authors:  Jürgen Rehm
Journal:  Int J Methods Psychiatr Res       Date:  2008-06       Impact factor: 4.035

7.  Why people change? The role of cognitive-control processes in the onset and cessation of substance abuse disorders.

Authors:  Gerhard Bühringer; Hans-Ulrich Wittchen; Katrin Gottlebe; Claudia Kufeld; Thomas Goschke
Journal:  Int J Methods Psychiatr Res       Date:  2008-06       Impact factor: 4.035

8.  Estimates of people who injected drugs within the last 12 months in Belgium based on a capture-recapture and multiplier method.

Authors:  Els Plettinckx; Forrest W Crawford; Jérôme Antoine; Lies Gremeaux; Luk Van Baelen
Journal:  Drug Alcohol Depend       Date:  2020-11-24       Impact factor: 4.492

9.  Estimating the prevalence of illicit opioid use in New York City using multiple data sources.

Authors:  Jennifer McNeely; Marc N Gourevitch; Denise Paone; Sharmila Shah; Shana Wright; Daliah Heller
Journal:  BMC Public Health       Date:  2012-06-18       Impact factor: 3.295

Review 10.  Shared gray matter alterations in subtypes of addiction: a voxel-wise meta-analysis.

Authors:  Mengzhe Zhang; Xinyu Gao; Zhengui Yang; Mengmeng Wen; Huiyu Huang; Ruiping Zheng; Weijian Wang; Yarui Wei; Jingliang Cheng; Shaoqiang Han; Yong Zhang
Journal:  Psychopharmacology (Berl)       Date:  2021-07-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.